摘要
目的:观察重组人生长激素(rhGH)治疗肝硬化引起的低清(白)蛋白血症的临床疗效。方法:选择血清清蛋白低于30g·L-1的肝硬化病人46例,男性39例,女性7例,分为治疗组、对照组各23例。治疗组在常规保肝及对症治疗基础上,给予rhGH,4IU,皮下注射,每日1次,连续14d;对照组仅给予常规保肝及对症治疗,14d为一个疗程。检测2组病人治疗前及治疗结束d1和4wk后血清清蛋白及其他肝功能指标变化,并进行临床观察。结果:治疗组治疗前血清清蛋白(25±s3)g·L-1,治疗结束d1血清清蛋白(31±3)g·L-1(P<0.01),4wk后血清清蛋白(33±3)g·L-1(P<0.01);对照组治疗前血清清蛋白(25±3)g·L-1,治疗结束d1血清清蛋白(25±3)g·L-1,4wk后血清清蛋白(24.4±2.6)g·L-1(P>0.05),2组治疗结束d1及4wk后血清清蛋白相比,差异有非常显著意义(P<0.01)。治疗结束d1及4wk内治疗组比对照组病人精神状态、食欲、尿量、腹腔积液、肝功能等均明显改善且持续稳定,有显著差异(P<0.05)。无明显不良反应。结论:rhGH可以增加肝硬化病人的血清清蛋白的水平,改善营养状况,无明显不良反应。
AIM：To evaluate the clinical efficacy of recombined human somatotropin （rhGH） in treatment of liver cirrhosis with hypoproteinemia. METHODS： Forty-six patients with hypoalbumia caused by liver cirrhosis were enrolled into this study （M 39,F 7 ）. All patients were divided into two groups （ with 23 patients in each for the experimental group and control group ）. Patients in experimental group received rhGH, 4 IU· d^- 1, sc, along with traditional therapy,while control group received traditional therapy only;the whole course covered 14 d. For each group serum albumin levels and other hepatic functions were measured before, the d 1 and 4 wk after the treatment,respectively. RESULTS：Serum albumin levels in experimental group showed significant differences between before treatment and d 1,4 wk after the treatment （（25±s 3） vs （31±3） vs （33±3） g· L^-1,P 〈0.01）, while control group showed no significant differences （ （25± 3 ） vs （ 25± 3 ） vs （24.4 ± 2.6） g ·L^-1, p 〉 0.05 ）. There were also remarkable differences between the two groups on the d 1 and 4 wk after the treatment （P 〈 0.01 ）. General condition of the experimental group including apetide, urine excretion volume ascites , liver function was obviously promoted and persisting stable than those of the controls （P 〈0.05）. No adverse reactions occured inexperimental group. CONCLUSION ： rhGH is effective, promising and less complication in the treatment of liver cirrhosis with hypoalbumia.
出处
《中国新药与临床杂志》
CAS
CSCD
北大核心
2005年第8期649-651,共3页
Chinese Journal of New Drugs and Clinical Remedies
